Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma

Cancer

Volumn 89, Issue 3, 2000, Pages 619-629

  Jahnson, Staffan ^a   Karlsson, Mats G ^a  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Bladder carcinoma; Cystectomy; mdm2; p21; p53; Prognosis; Tumor suppressor function

Indexed keywords

ONCOPROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER MORTALITY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034255307     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.0.CO;2-4     Document Type: Article

References (54)

1. The p53 tumour suppressor gene
2. The relevance of p53 mutation in urological malignancies: Possible clinical implications for bladder cancer
3. A molecular genetic model of human bladder cancer pathogenesis
4. The p53 tumour suppressor gene
5. Accumulation of tumor suppressor gene protein: An independent marker of prognosis in breast cancer
6. Association of p53 mutations with short survival in colorectal cancer
7. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis
8. P53 and RB1 protein expression: Are they prognostically useful in colorectal cancer?
9. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
10. Accumulation of nuclear p53 and tumor progression in bladder cancer
11. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
12. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy
13. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value
14. WAF1, a potential mediator of p53 tumor suppression
15. p21(WAF1) immunohistochemical expression in breast carcinoma: Correlations with clinopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival
16. p21(Waf1/Cip1) and p53 protein expression in breast cancer
17. Clinical and pathological associations with p53 tumour-suppressor gene mutations anal expression of p21(WAF1/CIP1) in colorectal carcinoma
18. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
19. Analysis of p21(WAF1/CIP1) in primary bladder tumors
20. Effect of p21(WAF1/CIP1) expression on tumor progression in bladder cancer
21. Evidence of a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells
22. Topological control of p21(WAF1/CIP1) expression in normal and neoplastic tissues
23. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
24. Mdm2 promotes the rapid degradation of p53
25. Regulation of p53 stability by Mdm2
26. mdm2 expression is induced by wild type p53 activity
27. The p53-mdm2-auto-regulatory feedback loop
28. Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma
29. Expression of mdm-2 and p53 protein in transitional cell carcinoma
30. Altered patterns of MDM-2 and TP53 in human bladder cancer
31. Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas
32. The role of p53, MDM2 and c-erb B2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer
33. Immunohistochemical analysis of p53 and proliferative cell nuclear antigen (PCNA) in bladder cancer: Positive immunostaining and radiosensitivity
34. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinopathological correlates
35. p53 overexpression as a prognostic factor for advanced stage bladder cancer
36. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy
37. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer
38. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
39. Interaction between the retinoblastoma protein and the oncoprotein MDM2
40. p53 protein expression in breast carcinomas Comparative study with the wild-type p53 induced proteins mdm2 and p21/waf1
41. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotype of human p53 mutants
42. p53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence
43. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
44. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
45. p53 status and the efficacy of cancer therapy in vivo
46. P53 gene mutation in B-cell chronic lymphatic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
47. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
48. A comparative study of p53 gene mutations, protein accumulation and response to chemotherapy in advanced ovarian carcinoma
49. p53 and treatment of bladder cancer
50. Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a carboplatin-based regimen (M-CAVI)
51. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer
52. p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy
53. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: An immunohistochemical study
54. The alternative product from the human CDKN2A locus, p14ARF, participates in the regulatory feedback loop with p53 and mdm2